Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
4.270
+0.070 (1.67%)
At close: Jun 4, 2026, 4:00 PM EDT
4.350
+0.080 (1.87%)
After-hours: Jun 4, 2026, 7:54 PM EDT
Bicycle Therapeutics Employees
Bicycle Therapeutics had 288 employees as of December 31, 2025. The number of employees decreased by 17 or -5.57% compared to the previous year.
Employees
288
Change (1Y)
-17
Growth (1Y)
-5.57%
Revenue / Employee
$220,472
Profits / Employee
-$760,524
Market Cap
298.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 288 | -17 | -5.57% |
| Dec 31, 2024 | 305 | 21 | 7.39% |
| Dec 31, 2023 | 284 | 48 | 20.34% |
| Dec 31, 2022 | 236 | 117 | 98.32% |
| Dec 31, 2021 | 119 | 32 | 36.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Rocket Pharmaceuticals | 202 |
| Lyell Immunopharma | 161 |
| Niagen Bioscience | 117 |
| Lineage Cell Therapeutics | 77 |
| InflaRx | 65 |
| Armata Pharmaceuticals | 61 |
| Immuneering | 55 |
| Surrozen | 44 |
BCYC News
- 14 days ago - Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting - Business Wire
- 5 weeks ago - Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies - TheFly
- 5 weeks ago - Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c) - TheFly
- 5 weeks ago - Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Business Wire
- 5 weeks ago - Bicycle Therapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Bicycle Therapeutics Earnings release: Q1 2026 - Filings
- 6 weeks ago - Bicycle Therapeutics Proxy statement: Proxy filing - Filings
- 6 weeks ago - Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting - Business Wire